UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

March 25, 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

March 23, 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the steps that can be taken to reduce potential exposure to coronavirus disease 2019 (COVID-19).

March 17, 2020

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

March 13, 2020

Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.

March 11, 2020

Sara A. Hurvitz, MD, discusses the need for additional research with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

March 04, 2020

Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.

February 26, 2020

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

February 20, 2020

Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.

January 17, 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.

January 16, 2020

Sara A. Hurvitz, MD, discusses treatment options for patients with HER2-positive metastatic breast cancer.

January 08, 2020

Madelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.

January 08, 2020

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.

October 09, 2019

Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.

September 25, 2019

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

September 16, 2019

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

September 13, 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

May 29, 2019

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

May 28, 2019

Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.

March 26, 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

March 21, 2019

Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.